Package Leaflet: Information for the Patient
Atorvastatin/Ezetimibe Cinfa 10 mg/10 mg Hard Capsules
Atorvastatin/Ezetimibe Cinfa 20 mg/10 mg Hard Capsules
Atorvastatin/Ezetimibe Cinfa 40 mg/10 mg Hard Capsules
Atorvastatin Calcium/Ezetimibe
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Pack
Atorvastatin/Ezetimibe Cinfa contains two different active substances in one capsule. One of the active substances is atorvastatin, which belongs to a group of medicines called statins, the other active substance is ezetimibe.
Atorvastatin/Ezetimibe Cinfa is a medicine used in adults to lower the levels of total cholesterol, "bad" cholesterol (LDL cholesterol) and substances called triglycerides that are circulating in the blood. It also raises the levels of "good" cholesterol (HDL cholesterol).
This medicine works by reducing cholesterol in two ways: it reduces the cholesterol absorbed in the gut and the cholesterol produced by the body itself.
For most people, high cholesterol does not affect how they feel. However, if left untreated, fatty deposits can build up in the walls of the blood vessels, narrowing them.
Sometimes, these narrowed blood vessels can become blocked, cutting off the blood supply to the heart or brain, leading to a heart attack or stroke. By lowering cholesterol levels, the risk of having a heart attack, stroke, or other health problems can be reduced.
This medicine is used in patients who cannot control their cholesterol levels by diet alone. While taking this medicine, you should also follow a low-cholesterol diet.
Your doctor may prescribe this medicine if you are already taking both medicines, atorvastatin and ezetimibe, at the same dose level, in addition to your cholesterol-lowering diet, if you have:
This medicine does not help you lose weight.
Do not take Atorvastatin/Ezetimibe Cinfa
Warnings and Precautions
Consult your doctor or pharmacist before taking this medicine:
Contact your doctor as soon as possible if you experience unexplained muscle pain, tenderness, or weakness while taking atorvastatin/ezetimibe.This is because, on rare occasions, muscle problems can be serious, including muscle breakdown causing kidney damage. Atorvastatin is known to cause muscle problems, and muscle problems have also been reported with ezetimibe.
Also, inform your doctor or pharmacist if you experience persistent muscle weakness. You may need to have tests and additional medicines to diagnose and treat this problem.
While you are taking this medicine, your doctor will check if you have diabetes or are at risk of developing diabetes. This risk of diabetes increases if you have high levels of sugars and fats in the blood, are overweight, and have high blood pressure.
Tell your doctor about all your medical problems, including allergies.
The combined use of Atorvastatin/Ezetimibe Cinfa and fibrates (certain cholesterol-lowering medicines) should be avoided, as the combined use of this medicine and fibrates has not been studied.
Children and Adolescents
Atorvastatin/Ezetimibe Cinfa is not recommended for children and adolescents under 18 years of age.
Other Medicines and Atorvastatin/Ezetimibe Cinfa
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
There are some medicines that can affect the way atorvastatin/ezetimibe works, or their effects can be altered by atorvastatin/ezetimibe. This type of interaction could reduce the effectiveness of one or both medicines. On the other hand, it could also increase the risk or severity of side effects, including a serious disorder in which muscle tissue breaks down, known as "rhabdomyolysis", which is described in section 4:
Taking Atorvastatin/Ezetimibe Cinfa with Food and Alcohol
See section 3 for instructions on how to take this medicine. Please note the following:
Grapefruit Juice
Do not drink more than one or two small glasses of grapefruit juice per day, as large amounts of grapefruit juice can affect the way this medicine works.
Alcohol
Avoid excessive alcohol consumption while taking this medicine. For more details, see section 2 "Warnings and Precautions".
Pregnancy and Breast-feeding
Do not take atorvastatin/ezetimibe if you are pregnant, if you are trying to become pregnant, or if you think you may be pregnant. Do not take this medicine if you can become pregnant, unless you use reliable contraceptive methods. If you become pregnant while taking this medicine, stop taking it immediately and inform your doctor.
Do not take atorvastatin/ezetimibe if you are breast-feeding.
The safety of this medicine during pregnancy and breast-feeding has not yet been proven.
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and Using Machines
Atorvastatin/ezetimibe is not expected to affect your ability to drive or use machines. However, it should be noted that some people may experience dizziness after taking this medicine. If you feel dizzy, consult your doctor before driving or using machines.
Atorvastatin/Ezetimibe Cinfa Contains Sucrose and Sodium
This medicine contains sucrose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per capsule; this is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
You should continue with a cholesterol-lowering diet while taking this medicine.
The recommended daily dose for adults is one capsule of the indicated dose.
Take Atorvastatin/Ezetimibe Cinfa once a day.
You can take the capsules at any time of the day, with or without food. However, try to take the capsule at the same time each day.
Swallow each capsule whole with water.
This medicine is not suitable for initiating treatment. The start of treatment or dose adjustments, if necessary, should only be done by taking the active substances separately, and once the appropriate doses have been adjusted, it is possible to switch to atorvastatin/ezetimibe of the corresponding dose.
If your doctor has prescribed atorvastatin/ezetimibe along with another cholesterol-lowering medicine containing the active substance colestyramine or any other bile acid sequestrant, you should take this medicine at least 2 hours before or 4 hours after taking the bile acid sequestrant.
If you take more Atorvastatin/Ezetimibe Cinfa than you should
If you accidentally take too many capsules (more than your recommended daily dose), contact your doctor or the nearest hospital for medical assistance.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Atorvastatin/Ezetimibe Cinfa
If you forget to take a dose, simply take the next scheduled dose at the planned time. Do not take a double dose to make up for forgotten doses.
If you stop taking Atorvastatin/Ezetimibe Cinfa
Consult your doctor if you want to stop taking atorvastatin/ezetimibe. Your cholesterol levels may increase again if you stop taking this medicine.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
If you experience any of the following serious adverse effects or symptoms, stop taking this medicine and immediately inform your doctor, or go to the emergency department of the nearest hospital.
Rare (may affect up to 1 in 1,000 people):
Very Rare (may affect up to 1 in 10,000 people):
Other Possible Adverse Effects
Frequent (may affect up to 1 in 10 people):
Infrequent (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Very Rare (may affect up to 1 in 10,000 people):
Frequency Not Known (cannot be estimated from available data):
Consult your doctor if you experience weakness in the arms or legs that worsens after periods of activity, double vision, or drooping eyelids, difficulty swallowing, or difficulty breathing.
Possible Adverse Effects Reported with Some Statins:
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is an adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es.
By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
This medicine does not require any special storage temperature. Keep this medicine out of sight and reach of children.
Store in the original packaging to protect it from moisture.
Do not use this medicine after the expiration date shown on the packaging and blister after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Atorvastatin/Ezetimibe cinfa
Core:
Calcium carbonate, hydroxypropylcellulose, polysorbate 80, sodium croscarmellose, sugar spheres (containing sucrose and cornstarch), talc, mannitol, microcrystalline cellulose, low-substituted hydroxypropylcellulose, povidone, sodium lauryl sulfate, and magnesium stearate.
Capsule shell:
Atorvastatin/Ezetimibe cinfa 10 mg/10 mg hard capsules:
Cap: titanium dioxide (E-171), yellow iron oxide (E-172), red iron oxide (E-172), black iron oxide (E-172), and gelatin.
Body: titanium dioxide (E-171), yellow iron oxide (E-172), and gelatin.
Atorvastatin/Ezetimibe cinfa 20 mg/10 mg hard capsules:
Cap: titanium dioxide (E-171), red iron oxide (E-172), and gelatin.
Body: titanium dioxide (E-171), yellow iron oxide (E-172), and gelatin.
Atorvastatin/Ezetimibe cinfa 40 mg/10 mg hard capsules:
Cap: titanium dioxide (E-171), yellow iron oxide (E-172), red iron oxide (E-172), black iron oxide (E-172), and gelatin.
Body: titanium dioxide (E-171), yellow iron oxide (E-172), and gelatin.
Appearance of Atorvastatin/Ezetimibe cinfa and Package Contents
Appearance:
Atorvastatin/Ezetimibe cinfa 10 mg/10 mg hard capsules
Hard gelatin capsule with no markings, size 0, with a caramel-colored cap and yellow body, filled with pellets and a tablet. The length of the capsule is approximately 21.7 mm.
Atorvastatin/Ezetimibe cinfa 20 mg/10 mg hard capsules
Hard gelatin capsule with no markings, size 0, with a reddish-brown cap and yellow body, filled with pellets and a tablet. The length of the capsule is approximately 21.7 mm.
Atorvastatin/Ezetimibe cinfa 40 mg/10 mg hard capsules
Hard gelatin capsule with no markings, size 0, with a dark brown cap and yellow body, filled with pellets and a tablet. The length of the capsule is approximately 21.7 mm.
Capsule filling:
IR Atorvastatin pellets: Spherical pellets.
Ezetimibe 10 mg tablet:
A cylindrical, flat tablet with a beveled edge, with a stylized E engraved on one face of the tablet and 612 engraved on the other face.
Package Contents:
OPA/Al/PVC/Al blisters in cartons of 30 hard capsules.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) – Spain
Manufacturer
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) – Spain
or
Egis Pharmaceuticals PLC, Site 2.
1165 Budapest, Bökényföldi út 118-120.
Hungary
or
Egis Pharmaceuticals PLC, Site 3
9900 Körmend, Mátyás király utca 65.
Hungary
Date of Last Revision of this Leaflet: April 2025
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/XXXXX/P_XXXXX.html
QR code to: https://cima.aemps.es/cima/dochtml/p/XXXXX/P_XXXXX.html